Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors

Neoplasia

Volumn 11, Issue 9, 2009, Pages 846-855

  Meeran, Syed M ^a   Katiyar, Nandan ^a   Singh, Tripti ^a   Katiyar, Santosh K ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12P40; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ORIDONIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT INTERLEUKIN 12; SERINE; SYNAPTOPHYSIN; SYNAPTOTAGMIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR MODEL; TUMOR VOLUME; ULTRAVIOLET IRRADIATION; WILD TYPE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLIN D1; FEMALE; FLOW CYTOMETRY; IN SITU NICK-END LABELING; INTERLEUKIN-12; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS, RADIATION-INDUCED; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 69249122382     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09528     Document Type: Article

References (34)

1. Trinchieri G (1994). Interleukin-12 a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84, 4008-4027.
2. Meeran SM, Mantena SK, Meleth S, Elmets CA, and Katiyar SK (2006). Interleukin-12-deficient mice are at greater risk of ultraviolet radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther 5, 825-832.
3. Maeda A, Schneider SW, Kojima M, Beissert S, Schwarz T, and Schwarz A (2006). Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 66, 2962-2969.
4. Meeran SM, Katiyar S, Elmets CA, and Katiyar SK (2007). Interleukin-12 deficiency is permissive for angiogenesis in UVradiation-induced skin tumors. Cancer Res 67, 3785-3793.
5. Katiyar SK (2007). Interleukin-12 and photocarcinogenesis. Toxicol Appl Pharmacol 224, 220-227.
6. Schwarz A, Ständer S, Berneburg M, Böhm M, Kulms D, van Steeg H, Grosse-Heitmeyer K, Krutmann J, and Schwarz T (2002). Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 4, 26-31.
7. Tyrrell RM (1996). Activation of mammalian gene expression by the UV component of sunlight-from models to reality. Bioessays 18, 139-148.
8. Sharma SD, Meeran SM, and Katiyar SK (2007). Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-κB signaling in in vivo SKH-1 hairless mice. Mol Cancer Ther 6, 995-1005.
9. Bode AM and Dong Z (2003). Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 167, 1-15.
10. Nomura M, Kaji A, Ma WY, Zhong S, Liu G, Bowden GT, Miyamoto KI, and Dong Z (2001). Mitogen- and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation. J Biol Chem 276, 25558-25567.
11. Datta SR, Brunet A, and Greenberg ME (1999). Cellular survival: a play in three Akts. Genes Dev 13, 2905-2927.
12. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, et al. (1997). Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100, 2961-2969.
13. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, and Van Waes C (1999). Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59, 3468-3474.
14. Pöppelmann B, Klimmek K, Strozyk E, Voss R, Schwarz T, and Kulms D (2005). NFκB-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J Biol Chem 280, 15635-15643.
15. Mittal A, Elmets CA, and Katiyar SK (2003). Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 24, 1379-1388.
16. Leung CH, Grill SP, Lam W, Han QB, Sun HD, and Cheng YC (2005). Novel mechanismof inhibition of nuclear factor-κ BDNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol 68, 286-297.
17. Meeran SM, Punathil T, and Katiyar SK (2008). Interleukin-12-deficiency exacerbates inflammatory responses in UV-irradiated skin and skin tumors. J Invest Dermatol 128, 2716-2727.
18. Brunda MJ, Luistro L,Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, and Gately MK (1993). Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 178, 1223-1230.
19. Saleem M, Afaq F, Adhami VM, and Mukhtar H (2004). Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 23, 5203-5214.
20. Luo J, Manning BD, and Cantley LC (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262.
21. Meeran SM and Katiyar SK (2008). Proanthocyanidins inhibit mitogenic and survival-signaling in vitro and tumor growth in vivo. Front Biosci 13, 887-897.
22. Rengifo-Cam W, Umar S, Sarkar S, and Singh P (2007). Antiapoptotic effects of progastrin on pancreatic cancer cells are mediated by sustained activation of nuclear factor-κB. Cancer Res 67, 7266-7274.
23. Baldwin AS (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 107, 241-246.
24. Guttridge DC, Albanese C, Reuther JY, Pestell RG, and Baldwin AS Jr (1999). NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19, 5785-5799.
25. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, and Hortobagyi G (2003). Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30, 93-104.
26. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, and Ito H (2004). Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 130, 8-14.
27. Downward J (1998). Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10, 262-267.
28. Callejas NA, Casado M, Bosca L, and Martin-Sanz P (1999). Requirement of nuclear factor κB for the constitutive expression of nitric oxide synthase-2 and cyclooxygenase-2 in rat trophoblasts. J Cell Sci 18, 3147-3155.
29. Carpenter CL and Cantley LC (1996). Phosphoinositide kinases. Curr Opin Cell Biol 8, 153-158.
30. Romashkova JA and Makarov SS (1999). NF-κB is a target of AKT in antiapoptotic PDGF signaling. Nature 401, 86-90.
31. Thanos D and Maniatis T (1995). NF-κ B: a lesson in family values. Cell 80, 529-532.
32. Baeuerle PA and Baltimore D (1996). NF-κ B: ten years after. Cell 87, 13-20.
33. Rayet B and Gelinas C (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947.
34. McCarty MF (1998). Polyphenol-mediated inhibition of AP-1 transactivating activity may slow cancer growth by impeding angiogenesis and tumor invasiveness. Med Hypotheses 50, 511-514.